Related Experiment Video
Updated: Aug 2, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Patent ductus arteriosus closure with a Nit-Occlud device. Experience with 13 cases]
Jaime E Munayer Calderón1, Tomás Aldana Pérez, José Luis Lázaro Castillo
1Hemodinamia, HG CMN La Raza. munayerjaime@90hotmail.com
Archivos De Cardiologia De Mexico
|March 21, 2006
Summary
The Nit-Occlud device shows promise for percutaneous closure of patent ductus arteriosus, achieving high occlusion rates with minimal complications in a small patient cohort.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Context:
- Patent ductus arteriosus (PDA) is a congenital heart defect requiring intervention.
- Percutaneous closure offers a less invasive alternative to surgical repair.
- Nitinol-based occluders represent an evolving technology for device closure.
Purpose:
- To evaluate the safety and efficacy of the Nit-Occlud device for percutaneous PDA closure.
- To assess early and mid-term occlusion rates and procedural complications.
- To analyze device performance across different PDA morphologies and sizes.
Summary:
- The study involved 13 patients (mean age 23.2 years) with PDA closure using Nit-Occlud devices.
- Immediate post-procedure, 25% achieved total occlusion, 54% had trivial leaks, and 16.6% had moderate-to-severe leaks.
- At 6-month follow-up, 15% had trivial leaks, with one device migration and one fatal endocarditis case.
Impact:
- The Nit-Occlud device demonstrates potential utility in PDA management.
- Further research is warranted to confirm its long-term effectiveness and safety profile.
- This study contributes to the understanding of device-based PDA closure outcomes.
